Weather

65°F4:05 AM

Health

1 read

Ibogaine Gains Attention as Potential Mental Health Treatment Under Trump Administration

KVIA•Wednesday, April 22, 2026 at 12:00 PM•CNN Newsource

Medical stethoscope representing healthcare news

Want the full story?

Read the complete article at KVIA

AI Summary

The Trump administration is focusing on psychedelic drugs, particularly ibogaine, as potential treatments for mental health issues. An executive order signed by President Trump includes a $50 million investment for research into these substances, aiming for expedited FDA approval. FDA Commissioner Dr. Marty Makary indicated that ibogaine could soon be approved for clinical use, allowing for human trials and paving the way for more research. While ibogaine is currently classified as a Schedule I substance, the new order may facilitate its use in controlled medical settings. This initiative is seen as a significant step towards addressing the mental health crisis in the U.S.

Key Details: • Executive order signed to fast-track research on psychedelics, including ibogaine. • FDA Commissioner expects ibogaine to be reviewed for approval within 1-2 months. • Ibogaine has been used in some countries for opioid withdrawal and mental health conditions. • Research facilities may soon be able to conduct studies on ibogaine in the U.S.

trump fda mentalhealth psychedelics ibogaine

People & Organizations

Donald TrumpFDAJoe RoganDEADr. Marty MakaryRick PerryKyrsten SinemaDr. Kirsten CherianDr. Arnt Schellekens

Related Articles

New Elite Lymphatics Institute Opens Its Doors in El Paso

The Elite Lymphatics Institute has officially launched its seventh location in El Paso, aiming to provide specialized lymphatic health services to the community. This new facility is designed to enhance wellness through advanced lymphatic drainage techniques, which are increasingly recognized for their health benefits. The opening of this institute is significant for residents seeking alternative health treatments, particularly in a city where such services are limited. Community members are encouraged to explore the offerings and consider the potential benefits for their health.

New Medicaid Work Requirements Could Impact Low-Income Residents in El Paso

A recently released rule outlines how states must enforce Medicaid work requirements, potentially complicating access to health coverage for low-income individuals, particularly those with health issues. This regulation affects 42 states, including Texas, and is part of the One Big Beautiful Bill Act. As these changes roll out next year, vulnerable populations may face increased challenges in maintaining their Medicaid benefits. Residents should stay informed about how these requirements might affect their healthcare access and consider advocating for supportive measures.

Immigration Detainees Report Widespread Medical Neglect in Facilities Nationwide

An investigation by KFF Health News and The Associated Press reveals that hundreds of immigration detainees in at least 33 states are filing federal lawsuits against detention facilities for inadequate medical care. Detainees report serious health issues, including untreated infections and cancer, highlighting a systemic problem within the immigration detention system. This situation raises concerns about the health and safety of individuals in custody and calls for reforms in how medical care is administered in these facilities. The findings emphasize the urgent need for oversight and accountability in the treatment of detainees.

Federal Charges Filed Against NIH Researchers for Monkeypox Smuggling Attempt

Two researchers from the National Institutes of Health (NIH) face federal charges for allegedly attempting to smuggle the monkeypox virus into the United States. This incident raises significant public health concerns, as monkeypox is a viral illness that spreads through close contact. The Department of Justice is taking this matter seriously, emphasizing the importance of biosecurity and the potential risks associated with unauthorized handling of infectious agents. The case highlights the need for stringent regulations and oversight in research involving dangerous pathogens.